Study Summary
This trial is testing a combination of two drugs to treat prostate cancer that has spread. The first drug, 177Lu-PSMA-617, is a radioactive agent that targets and kills cancer cells. The second drug, pembrolizumab, is an immunotherapy that helps the body's immune system attack the cancer. The combination of these two drugs may be more effective at treating prostate cancer than either drug alone.
- Carcinoma
- Stage IVA Prostate Cancer
- Stage IV Prostate Cancer
- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Malignant Neoplasms
- Adenocarcinoma
- Stage IVB Prostate Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 6 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab)
1 of 3
Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab)
1 of 3
Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab)
1 of 3
Experimental Treatment
43 Total Participants · 3 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 19th, 2021
Last Reviewed: November 11th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.